01/09/2026 Enhertu + pertuzumab secures EU approval as first-line treatment for HER2-positive breast cancer Enhertu + pertuzumab secures EU approval as first-line treatment for HER2-positive breast cancer (Ref) AstraZeneca & Daiichi Sankyo announced that Enhertu (trastuzumab deruxtecan; HER2-directed ADC) in combination with pertuzumab (HER2 dimerization-blocking monoclonal antibody) was approved in the European Union (EU) for the first-line treatment of adult patients with u